Oct 26 (Reuters) - Ginkgo Bioworks Holdings Inc DNA.N :
* SELECTA BIOSCIENCES AND GINKGO BIOWORKS ANNOUNCE PARTNERSHIP TO ADVANCE TREATMENTS FOR ORPHAN AND RARE DISEASES
* SELECTA BIOSCIENCES - LEVERAGING GINKGO'S CELL PROGRAMMING PLATFORM & CO'S IMMTOR PLATFORM TO CREATE POTENTIALLY TRANSFORMATIVE ENZYMATIC THERAPIES
* SELECTA BIOSCIENCES - GAINS RIGHTS TO DEVELOP, COMMERCIALIZE SELECT THERAPEUTIC ENZYMES FROM GINKGO'S ADVANCED ORGANISM ENGINEERING PLATFORM
* SELECTA BIOSCIENCES - GINKGO IS ELIGIBLE TO EARN CLINICAL AND COMMERCIAL MILESTONE PAYMENTS OF UP TO $85M IN CASH
* SELECTA BIOSCIENCES - GINKGO ELIGIBLE TO EARN UPFRONT RESEARCH & DEVELOPMENT FEES, MILESTONES, INCLUDING CERTAIN PAYMENTS IN FORM OF CO'S COMMON STOCK
Source text for Eikon: ID:nGNX7rtyW1 Further company coverage: DNA.N